Literature DB >> 33259649

Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.

Matthew R Woeste1, Neal Bhutiani1, Marilyn Donaldson1, Kelly M McMasters1, Nicolás Ajkay1.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) increases breast-conserving surgery (BCS) rates with comparable locoregional control and survival outcomes to adjuvant therapy. More women are receiving NAC and achieving pathologic complete responses (pCR). This study sought to evaluate the effect of NAC on surgical outcomes after the adoption of a "no-ink-on-tumor" margin policy in patients undergoing primary BCS (PBSC).
METHODS: An IRB approved database was queried for women undergoing BCS for invasive breast cancer after March 2014. We compared patients who underwent NAC followed by BCS versus PBCS. Demographic, tumor, treatment, and outcome variables were compared using both univariate and multivariable analysis.
RESULTS: A total of 162 patients were evaluated. NAC patients had significantly lower re-excision rates (0% NAC vs. 9% PBCS, p = .03), margin positivity (0% NAC vs. 5% PBCS, p = .01), and greater patient satisfaction with breast cosmesis (97 NAC vs. 77 PBCS, p = .01). On multivariable analysis, NAC was not an independent predictor of lower final resection volume, total complications, or greater satisfaction with breasts when controlling for age and T category at diagnosis.
CONCLUSION: NAC followed by BCS may offer less margin positivity, lower re-excision rates, and greater patient satisfaction when compared to a contemporary PBCS cohort in the "no-ink-on-tumor" era.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  breast cancer; lumpectomy; margins; neoadjuvant chemotherapy

Year:  2020        PMID: 33259649     DOI: 10.1002/jso.26301

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

Review 1.  Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer.

Authors:  Sneha Phadke
Journal:  Curr Oncol Rep       Date:  2022-10-01       Impact factor: 5.945

2.  Patients' Experiences of Care With or Without the Support of an Interactive App During Neoadjuvant Chemotherapy for Breast Cancer: Interview Study.

Authors:  Maria Fjell; Ann Langius-Eklöf; Marie Nilsson; Kay Sundberg
Journal:  JMIR Nurs       Date:  2022-08-11

3.  Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.

Authors:  Abolghasem Allahyari; Ali Ehsanpour; Nafiseh Ansarinejad; Valiollah Mehrzad; Behjat Kalantari; Jahangir Raafat; Mojtaba Ghadiany; Farhad Shahi; Behrooz Gharib; Vahid Moazed; Adnan Khosravi; Mir Hossein Mirpour; Sina Salari; Seyedmohammadreza Mortazavizadeh; Amirabbas Nekoyi; Mohsen Khani; Alireza Sadeghi; Sirus Gharib; Alireza Bary; Mehrzad Mirzania; Shirin Haghighat; Seyed Mohsen Razavi; Seyed Amir Hossein Emami; Mehran Hosseinzadeh; Mahdi Mirbolouk; Sanambar Sadighi; Abdolali Shahrasbi; Ali Esfahani; Masoumeh Gity; Nassim Anjidani; Hamidreza Kafi; Safa Najafi
Journal:  BMC Cancer       Date:  2022-09-07       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.